Cost-effectiveness analysis of augmentation therapy for severe α1-antitrypsin deficiency

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 10, 2003, Pages 1387-1392

  Gildea, Thomas R ^b   Shermock, Kenneth M ^b   Singer, Mendel E ^b   Stoller, James K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

1 antitrypsin deficiency; Cost effectiveness; Decision analysis

Indexed keywords

ALPHA 1 ANTITRYPSIN;

ADULT; ALPHA ANTITRYPSIN DEFICIENCY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; LUNG TRANSPLANTATION; MALE; MONTE CARLO METHOD; PREDICTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SIMULATION;

ALPHA 1-ANTITRYPSIN DEFICIENCY; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LONG-TERM CARE; MALE; MARKOV CHAINS; PROTEASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; REGISTRIES; RESPIRATORY FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 0037952677     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200209-1035OC     Document Type: Article

References (32)

1. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin: The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158:49-59.
2. Stoller JK, Rouhani F, Brantly M, Shahin S, Dweik RA, Stocks JM, Clausen J, Campbell E, Norton F. Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 2002;122:66-74.
3. Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991;81:427-433.
4. Alkins SA, O'Malley P. Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000;117:875-880.
5. Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha 1-antitrypsin deficiency [abstract]. Chest 2002;122:24S.
6. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease: American Thoracic Society. Am J Respir Crit Care Med 1995;152:S77-S121.
7. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
8. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford Medical Publications; 1997.
9. International Society for Pharmacoeconomics and Outcomes Research: ISPOR Lexicon, 1st ed. Princeton, NJ: ISPOR; 1998.
10. Drug topics: red book. Montville, NJ: Medical Economics Co., Inc.; 2001.
11. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285.
12. Sharples LD, Taylor GJ, Karnon J, Caine N, Buxton M, McNeil K, Wallwork J. A model for analyzing the cost of the main clinical events after lung transplantation. J Heart Lung Transplant 2001;20:474-482.
13. Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung transplantation. Chest 1995;108:1594-1601.
14. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy. J Clin Invest 1990;85: 1343-1352.
15. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: health utilities index. Pharmacoeconomics 1995;7:490-502.
16. Mullins CD, Huang X, Merchant S, Stoller JK. The direct medical costs of alpha (1)-antitrypsin deficiency. Chest 2001;119:745-752.
17. Stoller JK, Brantly M, Fleming LE, Bean JA, Walsh J. Formation and current results of a patient-organized registry for alpha(1)-antitrypsin deficiency. Chest 2000;118:843-848.
18. Trulock EP. Lung transplantation for alpha 1-antitrypsin deficiency emphysema. Chest 1996;110:284S-294S.
19. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant Statistics Annual Report: Lung Recipients, available online at URL:http://ustransplant.org/annual_reports/ar02/ar01_table_1204_d gn_lu.html, accessed 2002, June 1.
20. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L. Cost effectiveness of aspirin, ctopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002;346:1800-1806.
21. Wood AJ. When increased therapeutic benefit comes at increased cost. N Engl J Med 2002;346:1819-1821.
22. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med 1995;10:321-330.
23. Tsevat J, Duke D, Goldman L. Pfeffer MA, Lamas GA, Soukup JR, Kuntz KM, Lee TH. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914-919.
24. Littenberg B, Garber AM, Sox HC Jr. Screening for hypertension. Ann Intern Med 1990;112:192-202.
25. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991;9:199-208.
26. Lee KH, Angus DC, Abramson NS. Cardiopulmonary resuscitation: what cost to cheat death? Crit Care Med 1996;24:2046-2052.
27. Gage BF, Cardinalli AB, Albers GW, Owens DK Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-1845.
28. Hall J, Gerard K, Salkeld G, Richardson J. A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992;34:993-1004.
29. Willems JS, Sanders CR, Riddiough MA. Bell JC. Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 1980;303: 553-559.
30. Ramsey SD, Patrick DL, Albert RK, Larson EB, Wood DE, Raghu G. The cost-effectiveness of lung transplantation: a pilot study: University of Washington Medical Center Lung Transplant Study Group. Chest 1995;108:1594-1601.
31. Goeree R, Manalich J. Grootendorst P, Beecroft ML, Churchill DN. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995;18:455-464.
32. Chapman RH, Stone PW, Sandberg EA, Bell C, Neumann PJ. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000;20:451-467.